Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2026-02-04 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the company's CEO will participate in a fireside chat at an upcoming investor conference. It does not contain the actual presentation slides or detailed financial data, nor is it a formal regulatory filing or report. As it is a general announcement regarding company activities and investor relations, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate announcements that do not fit into more specific categories like 'Investor Presentation' (which would contain the actual slides) or 'Earnings Release'.
2026-02-04 English
Franchissement de seuil
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuil' (threshold crossing declaration). This is a regulatory requirement under Article L. 233-7 of the French Commercial Code, where a major shareholder (J.P. Morgan Chase & Co.) notifies the market that they have crossed the 5% ownership threshold in the company INVENTIVA. This fits the definition of a Major Shareholding Notification (MRQ).
2026-02-03 French
Franchissement de seuil
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuil' (threshold crossing declaration). It details that J.P. Morgan Chase & Co. has crossed below the 5% threshold of voting rights in the company INVENTIVA. This is a standard regulatory notification for major shareholding changes, which corresponds to the 'Major Shareholding Notification' category.
2026-01-30 French
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuils' (Declaration of crossing thresholds). This specifically refers to a major shareholder notifying the market that they have crossed a 5% ownership threshold in the company INVENTIVA. This aligns perfectly with the definition of a Major Shareholding Notification.
2026-01-30 French
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Transaction in Own Shares Classification · 100% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Half-year report on the liquidity contract) for the company Inventiva. This type of filing details the company's share buyback and sale activities conducted by a liquidity provider (Kepler Cheuvreux) over a six-month period. According to the provided definitions, reports detailing the company buying back or selling its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-26 French
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Transaction in Own Shares Classification · 95% confidence The document is a press release detailing the half-year report of a liquidity contract between Inventiva and Kepler Cheuvreux. It provides specific data on cash balances, share counts, and trading volumes for the period ending December 31, 2025. This type of disclosure regarding share buybacks and liquidity management is a standard regulatory requirement for companies listed on Euronext Paris. Since it reports on the company's own share transactions and liquidity account status, it falls under the category of 'Transaction in Own Shares'.
2026-01-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.